In September 2013, the advent of cancer genome analyses and the identification of potential therapeutic targets produced a shift in treatment strategies [10], and the introduction of “molecular therapy” with tyrosine kinase inhibitors proved to be beneficial in terms of survival compared to conventional chemotherapy for tumors harboring an EGFR (epidermal growth factor receptor) mutation [11]. This evidence concerns the gene EGFR and cancer.